Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patients

17 Mar 2021

Abstract excerpt

To identify a gemcitabine resistance-associated gene signature for risk stratification and prognosis prediction in pancreatic cancer. Pearson correlation analysis was performed with gemcitabine half maximal inhibitory concentration (IC50) data of 17 primary pancreatic cancer lines from Genomics of Drug Sensitivity in Cancer (GDSC) and the transcriptomic data from GDSC and Broad Institute Cancer Cell Line...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Pancreatic and Hepatic Oncology Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 33731794
DOI: 10.1038/s41598-021-85680-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A 14-gene gemcitabine resistance gene signature is significantly associated with the prognosis of pancreatic cancer patientsPMID 33731794Read ↗

Multidrug resistance genes screening of pancreatic cancer based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

Integrative Genomic Analysis of Gemcitabine Resistance in Pancreatic Cancer by Patient-derived Xenograft ModelsSemantic proximity Read ↗

A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinomaSemantic proximity Read ↗

Single-cell RNA sequencing revealed subclonal heterogeneity and gene signatures of gemcitabine sensitivity in pancreatic cancerSemantic proximity Read ↗

A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinomaSemantic proximity Read ↗

Multidrug resistance genes screening of pancreatic ductal adenocarcinoma based on sensitivity profile to chemotherapeutic drugsSemantic proximity Read ↗

ERAP2 as a potential biomarker for predicting gemcitabine response in patients with pancreatic cancerSemantic proximity Read ↗

A Thirteen-Gene Expression Signature Predicts Survival of Patients with Pancreatic Cancer and Identifies New Genes of InterestSemantic proximity Read ↗

The complement C3a/C3aR pathway is associated with treatment resistance to gemcitabine-based neoadjuvant therapy in pancreatic cancerSemantic proximity Read ↗

A 15-Gene Immune, Stromal, and Proliferation Gene Signature that Significantly Associates with Poor Survival in Patients with Pancreatic Ductal AdenocarcinomaSemantic proximity Read ↗

Development and clinical validation of a novel 9-gene prognostic model based on multi-omics in pancreatic adenocarcinoma.Semantic proximity Read ↗

Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenograftsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.